Latest Issue

Ophthalmic Drug Delivery169

Issue No #169 Mar 2025 March 22nd, 2025

Issue 169 - Mar 2025

Inside the magazine

A COMPREHENSIVE APPROACH TO ADDRESSING UNMET NEEDS IN INTRAVITREAL INJECTIONS

Dr Reza Abedian

A COMPREHENSIVE APPROACH TO ADDRESSING UNMET NEEDS IN INTRAVITREAL INJECTIONS

Dr Reza Abedian, Marie Stockton and Bernd Zeiss consider the complexities and clinical unmet needs of intravitreal injections and discuss how Gerresheimer’s syringe technology can help overcome these challenges.

GLAUCOMA IN VIEW: IMPROVING PATIENT ADHERENCE WITH MULTIDOSE EYEDROPPERS FOR PRESERVATIVE-FREE SOLUTIONS

GLAUCOMA IN VIEW: IMPROVING PATIENT ADHERENCE WITH MULTIDOSE EYEDROPPERS FOR PRESERVATIVE-FREE SOLUTIONS

Zoë Davidson considers the impact of glaucoma on global health and the challenges presented by the increasing prevalence of this disease in the ageing global population, discussing how Novelia®, Nemera’s multidose eyedropper for preservative-free formulations, is well-positioned to address many of the challenges presented by glaucoma treatments, from ease of use to sustainability.

GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES

GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES

Joe Batley and Lorna Barron provide an overview of the latest cutting-edge ophthalmic delivery methods and discuss possible future developments.

A NEW DELIVERY PLATFORM FOR SUPRACHOROIDAL ADMINISTRATION USING WEST’S ADVANCEABLE MICRONEEDLE DEVICE

Dr Anu Prabhathachandran

West Pharmaceutical Services

A NEW DELIVERY PLATFORM FOR SUPRACHOROIDAL ADMINISTRATION USING WEST’S ADVANCEABLE MICRONEEDLE DEVICE

Anu Prabhathachandran, Menachem Peretz and Manali Potnis discuss the growing need for more effective delivery of ophthalmic therapeutics to meet the needs of the ageing population, including how delivery into the suprachoroidal space may present an appealing alternative to intravitreal injection. They introduce West Pharmaceutical Service’ Suprachoroidal Advanceable Microneedle Device, which offers several advantages for overcoming the challenges with suprachoroidal space.

REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES

REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES

Binbin Tian discusses antisense oligonucleotides and considers their potential as treatments for genetic and multifactorial ophthalmic diseases previously considered untreatable. The article considers how these therapies function as treatments, their current state of development, challenges in their delivery and the evolving regulatory landscape

Top